Absence of nocturnal acid breakthrough in Helicobacter pylori-positive subjects treated with twice-daily omeprazole

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 5, 2004, Pages 445-450

  Martínek, Jan ^a   Pantoflíčková, Drahoslava ^b   Hucl, Tomáš ^a   Beneš, Marek ^a   Dorta, Gian ^b   Lukáš, Milan ^c   Špičák, Julius ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Helicobacter pylori infection; Intragastric pH; Nocturnal acid breakthrough; Omeprazole

Indexed keywords

OMEPRAZOLE;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEALTH STATUS; HELICOBACTER PYLORI; HUMAN; MALE; NIGHT; NONHUMAN; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID; STOMACH PH; TIME;

ADULT; BREATH TESTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS; STATISTICS, NONPARAMETRIC;

EID: 2342459667     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200405000-00002     Document Type: Article

References (24)

1. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic GORD Study Group. Gastroenterology 1999; 117:319-326.
2. Spencer CM, Faulds D. Esomeprazole. Drugs 2000; 60:321-329.
3. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93:763-767.
4. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12:1231-1234.
5. Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000; 14:709-714.
6. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115:1335-1339.
7. Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB Jr, et al. Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole. Dig Dis Sci 2002; 47:265-273.
8. Dodds WJ, Kahrilas PJ, Dent J, Hogan WJ, Kern MK, Amdorfer RC. Analysis of spontaneous gastroesophageal acid reflux and esophageal acid clearance in patients with reflux esophagitis. J Gastrointest Motil 1990; 2:79-89.
9. Korsten MA, Rosman AS, Fishbein S, Schlein RD, Goldberg HE, Biener A. Chronic xerostomia increases esophageal acid exposure and is associated with esophageal injury. Am J Med 1991; 90:701-706.
10. 2 blockers improve nocturnal acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15:1351-1356.
11. Kahrilas PJ. Strategies for medical management of reflux disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:775-791.
12. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal acid breakthrough. Gastroenterology 2002; 122:625-632.
13. Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Borsch G, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996; 31:1151-1156.
14. Labenz J, Tillenburg B, Peitz U, Idstrom JP, Verdú EF, Stolte M, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110:725-732.
15. Martínek J, Blum AL, Stolte M, Hartmann M, Verdú EF, Luhmann R, et al. Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13:27-34.
16. Katsube T, Adachi K, Kawamura A, Amano K, Uchida Y, Watanabe M, et al. Helicobacter pylori infection influences nocturnal acid breakthrough. Aliment Pharmacol Ther 2000; 14:1049-1066.
17. van Herwaarden MA, Samsom M, Smout AJ. Helicobacter pylori eradication increases nocturnal acid breakthrough. Aliment Pharmacol Ther 2000; 14:961-962.
18. Logan RP. Urea breath tests in the management of Helicobacter pylori infection. Gut 1998; 43 (suppl 1):S47-S50.
19. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161-1181.
20. Khoury RM, Katz PO, Hammod R, Castell DO. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999; 13:675-678.
21. Martínek J, Kužela L, Špičák J, Vavrecka A. Review article: the clinical influence of Helicobacter pylori in effective acid suppression - implications for the treatment of gastro-esophageal reflux disease. Aliment Pharmacol Ther 2000; 14:979-990.
22. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117:11-16.
23. Yeomans ND, Tulassay Z, Juhász L, Racz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338:719-726.
24. van Herwaarden MA, Samsom M, van Nispen CH, Mulder PG, Smout AJ. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999; 13:731-740.